A medical device determining the daily amount of breast milk to improve neonatal...
A medical device determining the daily amount of breast milk to improve neonatal nutrition andmothers psychophysics well being.
"Biological diversity among people, reveals that not all mothers are the same. For some of them (not a few) it occurs that they
are not able to successfully breastfeed their babies. Breastfeeding without ""feeding"" can cause freq...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto Galastick
Duración del proyecto: 4 meses
Fecha Inicio: 2016-05-10
Fecha Fin: 2016-09-30
Líder del proyecto
GALASCREEN SRLS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"Biological diversity among people, reveals that not all mothers are the same. For some of them (not a few) it occurs that they
are not able to successfully breastfeed their babies. Breastfeeding without ""feeding"" can cause frequent crying and colic in
the newborn and nervousness in mothers, lack of confidence in their abilities and depression. A mother starts to feel
inadequate, undermining her psychological wellness. On the other hand, several mothers have breastmilk in excess and
could donate it to preterm infants in midwiferies, thus promoting the babies' health and reduce hospitals' costs.
Galascreen developed a proprietary disposable medical device, GalaStick, determining the lactation onset and the
progressively increasing daily amount of breastmilk. The stick uses a lateral flow immunochromatographic assay that works
simply detecting the presence (or absence) of a target analyte in the human milk sample. Such an easy to use stick not only improves the neonatal nutrition (warning if any feeding integration is needed), but also the psychological well-being of the mother. GalaStick has reached TRL 6 since a preliminary prototype has been tested with real human milk samples. More than 150 volunteer mothers and human milk donor mothers were successfully screened. Galascreen requires funding to engineer and industrialize the stick prototype and to get it medically certified as a medical device. Both key processes will be supervised and supported by the SME partner Omini Pharma. Phase 1 project will address a deep study on business development strategy and will define the value chain and the commercialization plan, together with assessing the regulatory procedures and certifications to be obtained by both the product and the company in order to be an active player on the medical market."